Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 3
2005 3
2006 3
2007 3
2008 2
2009 4
2010 2
2011 2
2012 5
2013 5
2014 3
2015 8
2016 11
2017 13
2018 25
2019 11
2020 8
2021 13
2022 10
2023 12
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free article. Clinical Trial.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Endoscopic features and clinical course of colorectal carcinoma resected by cold snare polypectomy.
Yoshii S, Hayashi Y, Nakamura T, Nishiyama O, Nagaike K, Nakamatsu D, Yamada T, Egawa S, Ogiyama H, Yamaguchi S, Inoue T, Uema R, Kato M, Inoue T, Tsujii Y, Shinzaki S, Iijima H, Michida T, Morii E, Takehara T. Yoshii S, et al. Among authors: kato m. J Gastroenterol Hepatol. 2023 Jun;38(6):948-954. doi: 10.1111/jgh.16145. Epub 2023 Feb 24. J Gastroenterol Hepatol. 2023. PMID: 36797208 Review.
Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma.
Yamamoto S, Kato M, Takeyama Y, Azuma Y, Yukimatsu N, Hirayama Y, Otoshi T, Yamasaki T, Fujioka M, Gi M, Wanibuchi H, Uchida J. Yamamoto S, et al. Among authors: kato m. Br J Cancer. 2023 Jun;128(12):2197-2205. doi: 10.1038/s41416-023-02244-8. Epub 2023 Apr 17. Br J Cancer. 2023. PMID: 37069346 Free PMC article.
Endoscopic appearance of esophageal xanthoma.
Hamada K, Uedo N, Kubo C, Tomita Y, Ishihara R, Yamasaki Y, Omori M, Arao M, Suzuki S, Iwatsubo T, Kato M, Tonai Y, Shichijo S, Matsuura N, Nakahira H, Kanesaka T, Yamamoto S, Akasaka T, Hanaoka N, Takeuchi Y, Higashino K, Okada H, Iishi H. Hamada K, et al. Among authors: kato m. Endosc Int Open. 2019 Oct;7(10):E1214-E1220. doi: 10.1055/a-0966-8544. Epub 2019 Oct 1. Endosc Int Open. 2019. PMID: 31579702 Free PMC article.
Inverted Pyloric Gland Adenoma of the Duodenum.
Ueda T, Kato M, Kitamura M, Aizawa S, Uedo N, Takeuchi Y. Ueda T, et al. Among authors: kato m. Am J Gastroenterol. 2023 Dec 20. doi: 10.14309/ajg.0000000000002603. Online ahead of print. Am J Gastroenterol. 2023. PMID: 37975598 No abstract available.
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Nishiyama N, Kita Y, Ito K, Kato M, Hatakeyama S, Matsushita Y, Naito S, Miyake M, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Nishiyama H, Kobayashi T, Kitamura H; Japan Urological Oncology Group. Nishiyama N, et al. Among authors: kato m. Anticancer Res. 2023 Nov;43(11):5041-5050. doi: 10.21873/anticanres.16703. Anticancer Res. 2023. PMID: 37909969
[Unmet Needs from the Cancer Patient Perspective].
Onishi H, Majima Y, Nishidate S, Moue Y, Azuma Y, Oshida T, Kato M, Gatellier L. Onishi H, et al. Among authors: kato m. Gan To Kagaku Ryoho. 2023 Nov;50(11):1144-1149. Gan To Kagaku Ryoho. 2023. PMID: 38056863 Japanese.
134 results